|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired_by
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:acquisition
|
gptkb:Baxalta_Incorporated
gptkb:NPS_Pharmaceuticals
gptkb:Alder_Bio_Pharmaceuticals
Dyax Corp.
|
|
gptkbp:ceo
|
gptkb:Flemming_Ornskov
|
|
gptkbp:employees
|
over 23,000
|
|
gptkbp:founded
|
gptkb:1986
|
|
gptkbp:founder
|
gptkb:Helen_O._M._Shire
|
|
gptkbp:headcount
|
23,000+
|
|
gptkbp:headquarters
|
Lexington, Massachusetts, USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Shire Pharmaceuticals Group plc
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:market_cap
|
$50 billion (2018)
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
|
|
gptkbp:products
|
gptkb:Adderall
gptkb:Cerezyme
gptkb:Fabrazyme
gptkb:Intuniv
gptkb:Lialda
gptkb:Replagal
gptkb:Vyvanse
Gaucher disease treatment
Hunter syndrome treatment
Attention deficit hyperactivity disorder (ADHD) treatment
|
|
gptkbp:research_focus
|
endocrinology
oncology
hematology
genetic diseases
neuroscience
immunology
gastroenterology
ophthalmics
|
|
gptkbp:revenue
|
$15.2 billion (2017)
|
|
gptkbp:specializes_in
|
rare diseases
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
SHPG
|
|
gptkbp:subsidiary
|
gptkb:Shire_Pharmaceuticals_Ireland_Limited
gptkb:Shire_US_Inc.
gptkb:Shire_Development_LLC
gptkb:Shire_International_Gmb_H
|
|
gptkbp:website
|
www.shire.com
|
|
gptkbp:bfsParent
|
gptkb:Shire_plc
|
|
gptkbp:bfsLayer
|
5
|